This is a single-center, randomized, two part, open-label, crossover study in healthy adult
subjects. Part A will evaluate the relative bioavailability of two new tablet formulations
compared to the current tablet formulation of GSK1349572 at 50 mg administered as single
doses each comprising of two 25 mg tablets. Pharmacokinetic samples from Part A will be
analyzed and, if at least one of the new formulations meets appropriate criteria and is
selected, Part B will be a single-sequence design conducted to evaluate food effect of the
selected new tablet formulation at one dose level. A subset of subjects enrolled in Part A
will continue in Part B. Safety evaluations and serial PK samples will be collected during
each treatment period. A follow-up visit will occur 7-28 days after the last dose of study
drug.